Biotech Values

[dewophile]

If memory serves (I don’t have search capability on this site) many years ago you posted about how investable rare conditions are after blockbuster sales were reported for a drug with a very small indication (I want to say novoseven). So this would represent a 180 on your part.
Maybe I’m remembering wrong.
Anyway the upside w targeted therapies is the high hit rate in development. Obviously you have to think through the commercial viability ahead of time. At 300k + a course there often is room for profit , but not in the billions like some of the other indications you cite